VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
174.920
-0.770 (-0.44%)
As of 12:07PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close175.690
Open175.530
Bid174.220 x 800
Ask174.390 x 1100
Day's Range172.720 - 176.905
52 Week Range136.500 - 194.920
Volume490,167
Avg. Volume1,163,892
Market Cap44.703B
Beta (3Y Monthly)1.84
PE Ratio (TTM)108.44
EPS (TTM)1.613
Earnings DateOct 24, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est198.27
Trade prices are not sourced from all markets
  • What's in Store for Anika Therapeutics (ANIK) in Q3 Earnings?
    Zacks45 minutes ago

    What's in Store for Anika Therapeutics (ANIK) in Q3 Earnings?

    Anika Therapeutics (ANIK) is scheduled to report third-quarter earnings on Oct 24.

  • Vertex Pharmaceuticals: Q3 Earnings Forecast
    Market Realist4 hours ago

    Vertex Pharmaceuticals: Q3 Earnings Forecast

    Vertex Pharmaceuticals (VRTX) is scheduled to report its third-quarter earnings on October 24. Analysts expect Vertex Pharmaceuticals’ revenues to increase 43.3% from $551.87 million in the third quarter of 2017 to $790.9 million in the third quarter of 2018. During the last four quarters, Vertex Pharmaceuticals’ revenue growth was 32.48%–45.33%.

  • Benzinga19 hours ago

    The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

    Biotech stocks are staging a rebound following the losses incurred in the week ended Oct. 12 amid catalysts that include the third-quarter earnings season and presentations at the European Society of Medical ...

  • Better Buy: CRISPR Therapeutics AG vs. Intellia Therapeutics Inc.
    Motley Foolyesterday

    Better Buy: CRISPR Therapeutics AG vs. Intellia Therapeutics Inc.

    Which stock wins in a matchup between these two gene-editing pioneers?

  • See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.
    Markit2 days ago

    See what the IHS Markit Score report has to say about Vertex Pharmaceuticals Inc.

    Vertex Pharmaceuticals Inc NASDAQ/NGS:VRTX

  • Why Proteostasis Therapeutics Tumbled 23.2% on Friday
    Motley Fool3 days ago

    Why Proteostasis Therapeutics Tumbled 23.2% on Friday

    Some investors booked profits following the company's recent cystic fibrosis trial data.

  • UAB researchers leading way on drug regimen battling cystic fibrosis
    American City Business Journals3 days ago

    UAB researchers leading way on drug regimen battling cystic fibrosis

    A triple combination drug has been shown to be effective in improving lung function for the majority of patients with cystic fibrosis.  The new therapy can provide therapeutic benefits for 90 percent of all patients with the disease, according to findings published in the New England Journal of Medicine. Researchers from UAB report the medication, which combines an experimental compound known as VX-659 with two existing medications, tezacaftor and ivacaftor, improved lung function by more than 12 percent.  VX-659, along with tezacaftor and ivacaftor, were developed by Boston-based Vertex Pharmaceuticals.  In November 2017, the same the combination of tezacaftor and ivacaftor produced a substantial improvement in lung function in patients with cystic fibrosis, with a particular set of mutations in the gene responsible for the disease.

  • Simply Wall St.3 days ago

    Why Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is A Financially Healthy Company

    Investors looking for stocks with high market liquidity and little debt on the balance sheet should consider Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). With a market valuation of US$47.4b, VRTX is a Read More...

  • Business Wire3 days ago

    Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene

    Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to

  • Investor's Business Daily4 days ago

    Growth Stocks Smacked Again As Market Correction Intensifies

    Growth stocks faced more selling pressure Thursday as the market correction intensified. Activision plunged on Call of Duty sales concerns.

  • Business Wire4 days ago

    Vertex Data Presented at North American Cystic Fibrosis Conference (NACFC) Demonstrate Rapid Progress Toward Expanding and Enhancing Options for Treating the Underlying Cause of Cystic Fibrosis

    Vertex Pharmaceuticals Incorporated (VRTX) today announced that eight scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines are being presented at the 32nd North American Cystic Fibrosis Conference taking place October 18-20, 2018 in Denver.

  • Vertex Pharmaceuticals (VRTX) Q3 Earnings Preview: What's Shaping Up?
    Zacks5 days ago

    Vertex Pharmaceuticals (VRTX) Q3 Earnings Preview: What's Shaping Up?

    Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • CELG vs. VRTX: Which Stock Should Value Investors Buy Now?
    Zacks5 days ago

    CELG vs. VRTX: Which Stock Should Value Investors Buy Now?

    CELG vs. VRTX: Which Stock Is the Better Value Option?

  • Business Wire6 days ago

    Vertex to Announce Third Quarter 2018 Financial Results on October 24

    Vertex Pharmaceuticals Incorporated (VRTX) will report its third quarter 2018 financial results on Wednesday, October 24, 2018 after the financial markets close. An archived webcast will be available on the company's website. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

  • 3 High-Reward Stocks From 3 Emerging Trends
    InvestorPlace10 days ago

    3 High-Reward Stocks From 3 Emerging Trends

    Today I want to tell you about three stocks, each in its own emerging trend, that have huge upside potential in the transformative years ahead. Gene editing is just what it sounds like. CRISPR Therapeutics (NASDAQ:CRSP) is one of the three leaders in the gene editing sector.

  • FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial
    American City Business Journals10 days ago

    FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial

    CRISPR and Vertex were preparing to test the the ability of a new gene-editing technology, CRISPR/Cas9, in cutting out and replacing disease-causing snippets of DNA when the FDA placed the hold in May.

  • How Is Vertex Pharmaceuticals Positioned in October?
    Market Realist10 days ago

    How Is Vertex Pharmaceuticals Positioned in October?

    Vertex Pharmaceuticals (VRTX) is focused on developing and bringing to market therapies that treat cystic fibrosis. Vertex Pharmaceuticals has key collaboration agreements with CRISPR Therapeutics (CRSP) to develop treatments for underlying genetic causes of human diseases by using CRISPR-Cas9 technology. It also uses Moderna Therapeutics to develop mRNA (messenger ribonucleic acid) therapeutics for cystic fibrosis, BioAxone to evaluate VX-210 as a treatment for spinal cord injuries, and Parion Sciences to develop epithelial sodium channel inhibitors to treat pulmonary diseases.

  • A Look at Vertex Pharmaceuticals’ Operational Performance
    Market Realist10 days ago

    A Look at Vertex Pharmaceuticals’ Operational Performance

    How Is Vertex Pharmaceuticals Positioned in October? Vertex Pharmaceuticals’ (VRTX) cost of sales was $104.38 million in the second quarter of 2018 compared to $71.2 million in the second quarter of 2017. It incurred selling, general, and administrative expenses of $137.3 million in the second quarter of 2018 compared to $127.25 million in the second quarter of 2017.

  • What Vertex Pharmaceuticals’ Valuation Trend Indicates
    Market Realist10 days ago

    What Vertex Pharmaceuticals’ Valuation Trend Indicates

    In October, there are 24 analysts covering Vertex Pharmaceuticals (VRTX) stock. Twenty of them have given the stock a “buy” or higher rating, and four have given it a “hold.” The mean rating for the stock is 1.83 with a target price of $198.27, implying an upside potential of 12.9% over Vertex Pharmaceuticals’ closing price of $175.66 on October 11.

  • Why CRISPR Therapeutics Stock Is Heading Higher Today
    Motley Fool11 days ago

    Why CRISPR Therapeutics Stock Is Heading Higher Today

    CRISPR Therapeutics' stock is jumping in response to a positive regulatory development for its lead therapy.

  • Investopedia11 days ago

    CRISPR Therapeutics Set to Surge After FDA Lifts Hold on Human Trial

    The Food and Drug Administration (FDA) has cleared the way for CRISPR Therapeutics Ltd. ( CRSP) and Vertex Pharmaceuticals Inc. ( VRTX) to start testing their genetically engineered treatment for sickle cell disease on U.S. patients. In a press release, the two companies said the FDA has now lifted its clinical hold, enabling them to begin trailing the experimental therapy. At the time, CRISPR and Vertex claimed that CTX001 was placed on hold because the FDA had additional questions as part of its review of the paperwork that companies submit for permission to start a clinical trial.

  • CNBC12 days ago

    After-hours buzz: SQ, FLR & more

    Check out the companies making headlines after the bell: Square SQ stock tumbled 8 percent in after-hours trading following news that CFO Sarah Friar is stepping down . Friar will stay at the company until December before departing to become CEO of Nextdoor, a localized social network for neighborhoods.

  • FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial
    American City Business Journals12 days ago

    FDA lifts hold on first-ever CRISPR/Cas9 gene-editing trial

    The FDA has lifted its hold on a highly anticipated gene-editing trial by CRISPR Therapeutics and Vertex Pharmaceuticals, allowing for the first company-backed trial in the U.S. to start by the end of the year.

  • MarketWatch12 days ago

    Crispr stock up 8% as company says FDA accepted new-drug application

    Shares of Crispr Therapeutics AG rose more than 8% in the extended session Wednesday after the company and Vortex Pharmaceuticals Inc. said the Food and Drug Administration has lifted a clinical hold and has accepted a new-drug application for their gene-editing treatment for sickle-cell disease. Shares of Vortex rose 0.6% after ending the regular trading day down 5%. Crispr shares closed 0.6% lower.

  • GlobeNewswire12 days ago

    CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for CTX001 for the Treatment of Sickle Cell Disease

    In addition to the acceptance of the IND announced today, CRISPR and Vertex previously announced that they had obtained approvals of Clinical Trial Applications for CTX001 in multiple countries outside the U.S. for both β-thalassemia and SCD. The companies remain on track to initiate a Phase 1/2 clinical study in SCD by the end of 2018 and are currently enrolling patients with transfusion dependent β-thalassemia in a Phase 1/2 trial in β-thalassemia in Europe. The elevation of HbF by CTX001 has the potential to alleviate transfusion-requirements for β-thalassemia patients and painful and debilitating sickle crises for sickle cell patients.